Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

In the latest research, scientists from Canada tracked nearly 3,000 Americans who used either semaglutide, the active drug in ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Hims & Hers Health ( NYSE: HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A ...

WHEN doctors told her she was overweight, former Big Brother star Narinder Kaur took a decision that could have claimed her ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...

While GLP-1 drugs are currently available in the market, the Food and Drug Administration (FDA) had declared a shortage of semaglutide supply since 2022 after its popularity skyrocketed following news ...

compared to 82.5% for cagrilintide and 70.2% for semaglutide, the comparator drugs. Following the announcement, Novo Nordisk's stock price plunged nearly 18%, according to the lawsuit. The ...